These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 19499991)

  • 1. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas.
    Castro I; Lima L; Seoane R; Lado-Abeal J
    Thyroid; 2009 Jun; 19(6):645-9. PubMed ID: 19499991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain.
    Palos-Paz F; Perez-Guerra O; Cameselle-Teijeiro J; Rueda-Chimeno C; Barreiro-Morandeira F; Lado-Abeal J; ; Araujo Vilar D; Argueso R; Barca O; Botana M; Cabezas-Agrícola JM; Catalina P; Dominguez Gerpe L; Fernandez T; Mato A; Nuño A; Penin M; Victoria B
    Eur J Endocrinol; 2008 Nov; 159(5):623-31. PubMed ID: 18694911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
    Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
    Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
    Tonacchera M; Chiovato L; Pinchera A; Agretti P; Fiore E; Cetani F; Rocchi R; Viacava P; Miccoli P; Vitti P
    J Clin Endocrinol Metab; 1998 Feb; 83(2):492-8. PubMed ID: 9467563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the extracellular domain of the thyrotropin receptor.
    Kopp P; Muirhead S; Jourdain N; Gu WX; Jameson JL; Rodd C
    J Clin Invest; 1997 Sep; 100(6):1634-9. PubMed ID: 9294132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substitutions of different regions of the third cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive, TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3',5'-cyclic adenosine monophosphate signal generation.
    Kosugi S; Okajima F; Ban T; Hidaka A; Shenker A; Kohn LD
    Mol Endocrinol; 1993 Aug; 7(8):1009-20. PubMed ID: 7901757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells.
    Porcellini A; Ruggiano G; Pannain S; Ciullo I; Amabile G; Fenzi G; Avvedimento EV
    Oncogene; 1997 Aug; 15(7):781-9. PubMed ID: 9266964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas.
    Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the mouse TSH receptor equivalent to human constitutively activating TSH receptor mutations also cause constitutive activity.
    Neumann S; Krohn K; Chey S; Paschke R
    Horm Metab Res; 2001 May; 33(5):263-9. PubMed ID: 11440271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of in vitro constitutive activity for four previously reported TSH receptor mutations identified in patients with nonautoimmune hyperthyroidism and hot thyroid carcinomas.
    Jaeschke H; Mueller S; Eszlinger M; Paschke R
    Clin Endocrinol (Oxf); 2010 Dec; 73(6):815-20. PubMed ID: 20846293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil.
    Nogueira CR; Kopp P; Arseven OK; Santos CL; Jameson JL; Medeiros-Neto G
    Thyroid; 1999 Nov; 9(11):1063-8. PubMed ID: 10595453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5.
    Karges B; Krause G; Homoki J; Debatin KM; de Roux N; Karges W
    J Endocrinol; 2005 Aug; 186(2):377-85. PubMed ID: 16079263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
    Paschke R
    Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors.
    Kosugi S; Ban T; Akamizu T; Kohn LD
    Mol Endocrinol; 1992 Feb; 6(2):168-80. PubMed ID: 1349156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital hypothyroidism with impaired thyroid response to thyrotropin (TSH) and absent circulating thyroglobulin: evidence for a new inactivating mutation of the TSH receptor gene.
    Tonacchera M; Agretti P; Pinchera A; Rosellini V; Perri A; Collecchi P; Vitti P; Chiovato L
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1001-8. PubMed ID: 10720030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas.
    Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E
    Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid.
    Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ras homolog enriched in striatum inhibits the functional activity of wild type thyrotropin, follicle-stimulating hormone, luteinizing hormone receptors and activating thyrotropin receptor mutations by altering their expression in COS-7 cells.
    Agretti P; De Marco G; Pinchera A; Vitti P; Bernal J; Tonacchera M
    J Endocrinol Invest; 2007 Apr; 30(4):279-84. PubMed ID: 17556863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia.
    Tonacchera M; Van Sande J; Cetani F; Swillens S; Schvartz C; Winiszewski P; Portmann L; Dumont JE; Vassart G; Parma J
    J Clin Endocrinol Metab; 1996 Feb; 81(2):547-54. PubMed ID: 8636266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis.
    Grasberger H; Van Sande J; Hag-Dahood Mahameed A; Tenenbaum-Rakover Y; Refetoff S
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2816-20. PubMed ID: 17456567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.